BioArctic's global license agreement with Bristol Myers Squibb for PyroGlutamate-amyloid-beta antibody program effective after antitrust clearance ...
STOCKHOLM , Feb. 20, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that BioArctic and its partner Bristol Myers Squibb (NYSE: BMY) have received clearance from...
Bristol-Myers Squibb: Cobenfy's Strong Launch And 2025 Growth Outlook
Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and broad Medicaid/Medicare coverage, supporting its blockbuster potential in schizophrenia and future label expansions. Despite a r...
BMY Gets Positive CHMP Opinion for Opdivo, Yervoy Combo and Breyanzi
The CHMP recommends approval of Bristol Myers' Opdivo plus Yervoy for the first-line treatment of hepatocellular carcinoma and Breyanzi for relapsed or refractory follicular lymphoma.
Should Bristol Myers Stock Be in Your Portfolio Pre-Q4 Earnings?
BMY is looking to turn its business around, banking on the strong uptake of new drugs. The recent spate of positive regulatory updates also bodes well for the stock.
Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts
Medicaid funding, totaling approximately $900 billion per year and serving around 72 million participants, and the 340B program are key focus areas for potential healthcare reforms.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
3 Cheap Dividend Stocks That Pay More Than Double the S&P 500 Average
Many stocks don't offer particularly high yields. The stocks in the S&P 500, for instance, average a yield of just 1.3%.
Why the Market Dipped But Bristol Myers Squibb (BMY) Gained Today
The latest trading day saw Bristol Myers Squibb (BMY) settling at $60.62, representing a +1.59% change from its previous close.
Bristol Myers Squibb Presents Results from CheckMate -8HW Analysis Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) Compared to Opdivo Mono...
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO--BMS Presents Results from CheckMate -8HW.
Bloomsbury inks new long-term supply deal with Amazon
Bloomsbury Publishing PLC (LSE:BMY), the home of authors such as Sarah J. Maas and J.K.
Bristol-Myers Squibb Company (BMY) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)
Bristol-Myers Squibb Company (NYSE:BMY ) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2024 10:30 AM ET Company Participants Chris Boerner - Chairman and Chief Executive Officer Confere...
Look Out, Interest Rate Cuts Could Be Over: Buy These High-Yield Passive Income Stars Now
When the Federal Reserve met in December, it threw the stock market and Wall Street a pretty big curveball when it revealed that the dot plot for interest rate cuts for 2025 had been lowered to jus...
Bristol Myers Stock Gains 11.4% in a Year: Time to Buy or Sell?
Bristol Myers stock has performed well in the past year, gaining 11%. We believe there is more room for further growth, and any dip in the share price can be used as a buying opportunity.
Bristol Myers Squibb (BMY) Stock Declines While Market Improves: Some Information for Investors
Bristol Myers Squibb (BMY) closed the most recent trading day at $56.59, moving -0.35% from the previous trading session.
Is Trending Stock Bristol Myers Squibb Company (BMY) a Buy Now?
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Related Companies